Clinical trials
Relapsed or Refractory Hematologic Malignancies clinical trials
Below are recruiting relapsed or refractory hematologic malignancies clinical trials, each written for real people, not researchers. We’re tracking 1,347 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04902443RecruitingPhase 1
Pomalidomide plus nivolumab for virus-related cancers
This trial studies pomalidomide plus nivolumab in people with cancers linked to certain viruses (or hepatitis B/C). It may help the immune system fight the cancer when the disease has returned, progressed, or can’t be fully treated with standard options.
Bethesda, MarylandAges 18–99 - NCT04919538Recruiting
Long-term study of relapsing polychondritis
This study follows people who have been diagnosed with relapsing polychondritis over time. It aims to better understand the condition and how it progresses, which may help future care.
Philadelphia, PennsylvaniaAges Any age - NCT05035745RecruitingPhase 1/Phase 2
Selinexor plus talazoparib for advanced triple-negative breast cancer
This trial tests selinexor plus talazoparib in people with advanced, treatment-resistant solid tumors and, separately, advanced triple-negative breast cancer. It aims to see whether this combination can shrink tumors or slow their growth when standard options have not worked.
SingaporeAges 18–99 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05163301Recruiting
Alcohol relapse prevention for adults living with HIV
This study looks at ways to help people with HIV reduce the chance of heavy drinking coming back after a period of lower-risk drinking. It will use regular patient-reported check-ins about alcohol use to understand relapse patterns and test the approach’s impact.
Baltimore, MarylandAges 18 years+ - NCT05271292RecruitingPhase 1/Phase 2
Chiauranib for advanced cancers that returned or won’t respond
This Phase 1/2 study tests chiauranib in people with advanced solid cancers (including small cell lung cancer) that have come back or no longer respond to standard treatments. It aims to find a safe dose and see whether the treatment can help shrink tumors.
Encinitas, CaliforniaAges 18 years+ - NCT05512351RecruitingPhase 2
Immunotherapy plus low-dose Avastin for recurrent oligodendroglioma
This Phase 2 trial tests an immune treatment (sintilimab, an anti–PD-1 antibody) together with low-dose bevacizumab (Avastin) to treat oligodendroglioma that has come back, including cases detected by tumor DNA in body fluid. It aims to slow or control tumor growth and help reduce symptoms by targeting both the tumor and its blood supply.
Zhengzhou, HenanAges 18 years+ - NCT05527795Recruiting
Study features that predict benefit from extra immunotherapy in melanoma
This study looks for lab and tumor features that may help predict who benefits from follow-up (adjuvant) immunotherapy after surgery for melanoma. Your past treatment and tumor samples may be used to improve future treatment decisions.
Pierre-BéniteAges 18 years+ - NCT05607329Recruiting
Surgery plus chemo versus chemo alone for ovarian cancer relapse
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
Hangzhou, ZhejiangAges 18–70 - NCT05615636RecruitingPhase 2
Study of four medicines for relapsed B-cell lymphoma
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Houston, TexasAges 18 years+ - NCT05672147RecruitingPhase 1
CD33 CAR T cells for hard-to-treat AML
This Phase 1 study tests a personalized immune-cell treatment (CD33 CAR T cells) for adults with AML that has returned or did not respond to treatment. It aims to see how safe the therapy is and how well it works for AML cells that carry the CD33 marker.
Duarte, CaliforniaAges 18 years+ - NCT05757310RecruitingPhase 1
Stem cell transplant with lower-intensity chemo for severe aplastic anemia
This Phase 1 trial tests a “lower-intensity” chemotherapy plan followed by a stem cell transplant from a related half-match donor for severe aplastic anemia that has returned or did not respond to prior medicines. It aims to see if this approach is safe and works well enough to help your blood counts recover.
Duarte, CaliforniaAges Up to 75 years - NCT05758831RecruitingPhase 3
Rituximab vs ocrelizumab for relapsing multiple sclerosis
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
Lyon, BronAges 18–55 - NCT05789303RecruitingPhase 2
Belantamab plus other medicines for relapsed multiple myeloma
This Phase 2 study tests whether belantamab mafodotin combined with carfilzomib, pomalidomide, and dexamethasone can better treat multiple myeloma that has come back. It may help people who have already tried other myeloma treatments but whose cancer has progressed again.
Chicago, IllinoisAges 18 years+ - NCT05796570RecruitingPhase 2
Decitabine plus filgrastim to prevent relapse after transplant
This trial tests whether giving decitabine with filgrastim soon after a stem cell transplant can be done safely and may help prevent the leukemia or related cancer from coming back. It is aimed at children and young adults with AML, MDS, or related myeloid cancers.
Boston, MassachusettsAges 1–39 - NCT05834855RecruitingPhase 3
Rituximab versus ocrelizumab for relapsing multiple sclerosis
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
AmsterdamAges 18 years+ - NCT05870995RecruitingPhase 2
Chemo plus targeted conditioning for hard-to-treat AML
This trial studies a specific chemotherapy plan (called sequential CLAG-Ven) with a gentler “conditioning” treatment before a transplant or donor-based therapy. It may help people with refractory or quickly relapsing acute myeloid leukemia (AML) who have a suitable family or matched donor and can meet certain organ function and infection rules.
Shanghai, Shanghai MunicipalityAges 16–65 - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT05984147RecruitingPhase 1
Study of oral drug AUR108 for advanced lymphoma
This trial tests an experimental oral drug called AUR108 for people with advanced lymphoma that has come back after at least two prior treatments. The goal is to see if the drug is safe and if it can help shrink or control the lymphoma.
Visakhapatnam, Andhra PradeshAges 18–99 - NCT06211335RecruitingPhase 1
Losartan, pembrolizumab and radiation for advanced head & neck cancer
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Sacramento, CaliforniaAges 18 years+ - NCT06252792Recruiting
Daratumumab-pomalidomide-dexamethasone for first-relapse myeloma
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
Changchun, JilinAges 18 years+ - NCT06287398RecruitingPhase 2
Epcoritamab and chemo before stem cell transplant for relapsed large B-cell lymphoma
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
Melbourne, VictoriaAges 18 years+ - NCT06378437RecruitingPhase 1
GLB-001 for blood cancers that have returned or not responded
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
Hefei, AnhuiAges 18 years+ - NCT06386705RecruitingPhase 1
Testing TSN084 for advanced cancers
This trial tests an experimental drug called TSN084 for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory hematologic malignancies?
- Yes. Clin2 currently lists 1,347 recruiting relapsed or refractory hematologic malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory hematologic malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory hematologic malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Malignancies
- Relapsed/Refractory Hematological Malignancies
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Acute Myeloid Leukemia
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Relapsed/Refractory B-cell Lymphoma
- Non-Hodgkin Lymphoma Refractory/ Relapsed
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.